<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000250.v1.p1" parentStudy="phs000250.v1.p1" createDate="2010-04-01" modDate="2011-07-06">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Mark J. Ratain</td><td>University of Chicago, Chicago, IL, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>CALGB 80303: Genome-Wide Association Study of Advanced Pancreatic Cancer Patients</StudyNameEntrez>
	<StudyNameReportPage>CALGB 80303:Genome-Wide Association Study of Advanced Pancreatic Cancer Patients - 	   A Randomized Phase III trial of Gemcitabine Plus Bevacizumab versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Clinical Trial</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>CALGB 80303 was a randomized, phase III study in advanced pancreatic cancer patients treated with Gemcitabine plus either 	Bevacizumab or placebo. No difference in overall survival (OS) was observed between the two arms. We prospectively collected 	germline DNA and conducted a genome-wide association study (GWAS).</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p> 		<ol> 			<li> No documented invasion of adjacent organs by CT scan</li> 			<li> No prior chemotherapy, radiation therapy, gemcitabine or bevacizumab treatment, thrombolytic agent treatment</li> 			<li> No recent invasive surgical procedures</li> 			<li> No significant history of bleeding events</li> 			<li> No clinically significant cardiovascular disease</li> 			<li> No recent arterial thrombotic events</li> 			<li> No evidence of CNS disease</li> 			<li> No serious active infection</li> 			<li> No serious or no-healing wound, ulcer or bone fracture</li> 			<li> Not hypersensitive to Chinese hamster ovary cell products</li> 			<li> No currently active second malignancy other than non-melanoma skin cancer</li> 			<li> No pregnancy or breast feeding</li> 			<li> Age &gt;=18</li> 			<li> ECOG performance status of 0 to 2 and adequate bone marrow, renal, and hepatic function</li> 		</ol> 	</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM" title="A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303" journal="2007 Annual ASCO Meeting"/>
		</Publication>
		<Publication>
			<Journal authors="Innocenti F, Owzar K, Cox N, Evans P, Kubo M, Hollis D, Mushiroda T, Kindler HL, Nakamura Y, Ratain MJ; University of Chicago, Chicago, IL; CALGB Statistical Center, Durham, NC; Center for Genomic Medicine, RIKEN, Tokyo, Japan" title="Heritable interleukin-17F (IL17F) gene variation and overall survival (OS) in pancreatic cancer patients (pts): Results from a genome-wide association study (GWAS) in CALGB 80303" journal="2009 Annual ASCO Meeting"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Pancreatic Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Mark J. Ratain</AttName>
			<Institution>University of Chicago, Chicago, IL, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="APTC" longName="For use in future research to learn about, prevent or treat cancer"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIGMS</DacName>
      <DacFullName>National Institute of General Medical Sciences DAC</DacFullName>
      <DacEmail>NIGMSDBGAPDataAccessCommitee@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000250.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000250.v1.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000250.v1.p1" FileName="DUC_PGRN-RIKEN-CALGB_80303_Genome-wide_Pharmacogenomic_Study_of_Gemcitabine_and_Bevacizumab_in_Advanced_Pancreatic_Cancer_final.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>For use in future research to learn about, prevent or treat cancer</ConsentName>
        <ConsentAbbrev>APTC</ConsentAbbrev>
        <UseLimitation>This data may be used only for genetic studies to learn about, prevent, or treat cancer. Data use must be limited to research and may not be used in any commercial applications or patents.  Investigators must state in the DAR their intention to publish or otherwise broadly share any findings from their study with the scientific community.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
